Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ExAblate therapy set for phase III US trials:

This article was originally published in Clinica

Executive Summary

InSightec is to begin the final leg of US clinical trials for its non-invasive, MRI-guided, high frequency ultrasound ablation device. The phase III trials will assess the product, the ExAblate system, as a treatment for breast tumours, or fibroadenomas. The system is also being investigated for the treatment of uterine fibroids and breast cancer. InSightec was established at the beginning of 1999 as a joint venture between Elbit Medical Imaging and GE Medical Systems.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel